{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:25:00Z","timestamp":1761171900337,"version":"build-2065373602"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Lung neuroendocrine carcinoma is a rare heterogeneous tumor with the characteristics of high invasiveness, low incidence, and poor survival prognosis. Currently, there is a lack of effective treatment measures, and treatment strategies are mostly extrapolated from small cell lung cancer and non-small cell lung cancer protocols. Studies have shown that more than 55% of patients with extensive-stage small cell lung cancer experience grade 3 or higher myelosuppression after receiving platinum\/etoposide-containing chemotherapy, including neutropenia, anemia, and thrombocytopenia. myelosuppression can also increase the risks of infection, bleeding, etc. Severe myelosuppression may delay treatment, reduce dosage, stop medication, and cause other risks that affect tumor prognosis. The results of the study showed that the incidence of grade 3 or higher myelosuppression in patients using trilaciclib (a cyclin-dependent kinase 4\/6 [CDK4\/6] inhibitor) when receiving platinum-based chemotherapy was significantly lower than that in patients who did not use this drug. In addition, the use of trilaciclib did not affect the anti-tumor effects of chemotherapy and immunotherapy agents during the chemotherapy cycle. This study aimed to explore the effect of trilaciclib on chemotherapy-induced myelosuppression (CIM) in patients with pulmonary neuroendocrine carcinoma undergoing chemotherapy, and to provide a reference for improving patients\u2019 treatment tolerance and quality of life in clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2025.1685910","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:28Z","timestamp":1761106648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Analysis of short-term clinical efficacy of trilaciclib in patients with advanced lung neuroendocrine carcinoma undergoing chemotherapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.critrevonc.2019.102837","article-title":"Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia","volume":"145","author":"Abdel-Razeq","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac074a","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219622","article-title":"Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: a systematic literature review (SLR)","volume":"14","author":"Povsic","year":"2019","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0754","article-title":"Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings","volume":"18","author":"Goldschmidt","year":"2022","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01909-1","article-title":"Advances in treatment of recurrent small cell lung cancer(SCLC): insights for optimizing patient outcomes from an expert roundta ble discussion","volume":"38","author":"Das","year":"2021","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical characterization of G1T28: a novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann Onco."},{"key":"B11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 inhibition protects hematopoietic stem cells from 700","volume":"87","author":"He","year":"2021","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-893","article-title":"Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy\u2014a real-world study","volume":"16","author":"Chen","year":"2024","journal-title":"J Thorac Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1156821","article-title":"Bloodstream infections in neutropenic cancer patients: A practical update","volume":"7","author":"Gustinetti","year":"2016","journal-title":"Virulence."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3277-0","article-title":"Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid Malignancies","volume":"24","author":"Li","year":"2016","journal-title":"Support Care Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10125","article-title":"Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer","volume":"17","author":"Cheng","year":"2019","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cllc.2019.07.005","article-title":"Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133)","volume":"20","author":"Nishio","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-8179.2019.03.239.","article-title":"Comparison of efficacy and safety of three-drug combination chemotherapy and single-agent topotecan in second-line treatment of small cell lung cancer","volume":"46","author":"Zhang","year":"2019","journal-title":"Chin J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200220","article-title":"Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients","volume":"26","author":"Karimi","year":"2023","journal-title":"J Clin Hypertension."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02601-2","article-title":"Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy","volume":"40","author":"Goldschmidt","year":"2023","journal-title":"Adv Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01508-y","article-title":"Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use","volume":"39","author":"Kim","year":"","journal-title":"Drugs Aging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12885-024-12181-1","article-title":"Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia: analyzing the economic and clinical challenges","volume":"24","author":"Alyamany","year":"2024","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00520-022-07468-9","article-title":"Effects of granulocyte colony-stimulating factor (G-CSF) in the prevention of chemotherapy-induced febrile neutropenia in cancer patients","volume":"31","author":"Weiss","year":"2023","journal-title":"Supportive Care Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04879-x","article-title":"Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study","volume":"30","author":"Aras","year":"2022","journal-title":"Supportive Care Cancer."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07103-5","article-title":"Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF) management: evaluating patient and economic burdens of treatment methods","volume":"30","author":"Link","year":"","journal-title":"Supportive Care Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1685910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:36Z","timestamp":1761106656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1685910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1685910"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1685910","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1685910"}}